JavaScript seem to be disabled in your browser.
You must have JavaScript enabled in your browser to utilize the functionality of this website.
New catalog number DVV00308
Tixagevimab (AZD8895 or COV2-2196) was derived from B-cells donated by convalescent patients after SARS-CoV-2 viral infection. AZD8895 is able to block the binding of the SARS-CoV-2 virus to host cells and protect against infection in cell and animal models of disease.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). The structural proteins of SARS-CoV-2 include the envelope protein (E), spike or surface glycoprotein (S), membrane protein (M) and the nucleocapsid protein (N). Spike glycoprotein is cleaved into the following 3 chains, Spike protein S1, Spike protein S2, Spike protein S2'. Spike protein S1 attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Spike glycoprotein is an important target for vaccine development, antibody therapies and diagnostic antigen-based tests.